
    
      This study is a prospective open-label, non-randomized multicenter phase I/II trial in order
      to determine overall response rate of patients with platinum-resistant or refractory
      recurrent, pretreated epithelial ovarian cancer.

      In order to assure adequate toxicity assessment, a phase-I-trial is proponed. Phase II will
      be performed with MTD.
    
  